Format

Send to

Choose Destination
Hepatology. 2010 Jul;52(1):360-9. doi: 10.1002/hep.23633.

Sorafenib: where do we go from here?

Author information

1
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. aas54@columbia.edu

Abstract

The approval of sorafenib as the first effective drug for the treatment of hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. A better understanding of HCC pathogenesis has led to the development of several novel targeted treatments. HCC is treated in a uniquely multidisciplinary way requiring surgeons, hepatologists, interventional radiologists, and oncologists. This review describes the molecular pathogenesis of HCC, explores current and future treatments based on these pathways, and describes how these new therapies may augment existing approaches to HCC treatment.

PMID:
20578152
PMCID:
PMC3605708
DOI:
10.1002/hep.23633
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center